Thus, plasma p-tau231 demonstrates excellent clinical utility as a rapid screening test for AD but may serve as a superior staging biomarker of emerging AD pathology allowing clinical trials to targeting vulnerable populations under the threshold of Aβ positivity and early tau deposition. Here, MAPT is linked to Alzheimer disease.